Our data shows ST6GAL1 is 1.7-fold higher in prostate-derived tumours growing in bone compared to tumours biopsied at the primary site (unpaired t test, p = 0.0103) (Fig. 2a). This evidence concerns the gene ST6GAL1 and neoplasm.